How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

879 results for

Actinic Keratoses

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial. Photodynamic therapy (PDT) is an effective and cosmetically favorable treatment modality for actinic keratoses (AKs). However, prolonged incubation times and pain associated with treatment are burdensome to the patient and a hindrance to widespread use of PDT as standard field therapy for AK.To evaluate efficacy and pain associated with microneedle expedited

2017 JAMA dermatology (Chicago, Ill.) Controlled trial quality: predicted high

42. Actinic Keratoses

Actinic Keratoses Actinic Keratoses Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Actinic Keratoses Actinic Keratoses Aka: Actinic (...) Keratoses , Actinic Keratosis From Related Chapters II. Epidemiology Most common premalignant skin lesion Responsible for 60% of involving the skin : White skin (increases with age) Age 20-29: 10% Age 80-89: 75% III. Pathophysiology Superficial keratotic tumor Previously considered distinct premalignant changes Now thought to be very early s IV. Risk Factors Fair-skinned, blue-eyed persons Living in sunny climate Cummulative extensive Older persons V. Symptoms Typically asymptomatic May be pruritic

2018 FP Notebook

43. Many interventions effective for actinic keratoses

Many interventions effective for actinic keratoses Many interventions effective for actinic keratoses | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Many interventions effective for actinic keratoses Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2013 Cochrane PEARLS

44. Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V

Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Ingenolmebutat (aktinische Keratose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 November 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A18-55 Ingenol mebutate (actinic keratosis) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A18-55 Version 1.0 Ingenol mebutate (actinic keratosis) 29 November 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ingenol mebutate (actinic keratosis) – Benefit assessment according to §35a

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

46. Actinic Keratoses, Actinic Field Change and Associations with Squamous Cell Carcinoma in Renal Transplant Recipients in Manchester, UK. Full Text available with Trip Pro

Actinic Keratoses, Actinic Field Change and Associations with Squamous Cell Carcinoma in Renal Transplant Recipients in Manchester, UK. While actinic keratoses (AKs) have a known association with cutaneous squamous cell carcinoma (SCC), the relation of actinic field change to SCC has not been quantified. This study investigated the presence of field change and AKs in renal transplant recipients (RTRs) and estimated SCC risk. In May 2010 to October 2011, a dermatologist examined 452 white RTRs (...) (mean age 53 years) at two hospitals in Manchester, UK, counting AKs and recording field change presence by body site and SCCs arising during the study period. Of the participants 130 (29%) had AKs at examination. In 60 (13%) RTR patients with AKs but no field change, 4 (7%) developed SCCs, compared with 15 (21%) of the 70 (15%) with AKs and field change. SCCs developed directly within field change areas in 11/15 (73%) RTRs. This study confirms that RTRs with widespread confluent actinic skin damage

2015 Acta Dermato-Venereologica

47. Imiquimod (Zyclara) - actinic keratosis

respectively. 4 The SPC notes that some systemic adverse events, including headache (6.2% [10/160]) and fatigue (4.4% [7/160]), were reported by imiquimod 3.75% treated patients during the two key studies. 1 5 Summary of clinical effectiveness issues Actinic keratoses are chronic keratotic lesions on sun-exposed skin which have a low risk (=1 in 1,000) of developing into invasive squamous cell carcinomas. It is not possible to determine which lesions are most likely to progress. Treatment is based (...) and £80k in year 1 and year 5, respectively. 11 References 1. Meda Pharma Gmb H. Zyclara 3.75% cream - Summary of Product Characteristics (SmPC). 2018. 2. European Medicines Agency (EMA) European Public Assessment Report imiquimod (Zyclara). 03/08/2012 EMEA/H/C002387 3. Meda Pharma Gmb H. Aldara 5% Cream - Summary of Product Characteristics (SmPC). 2017. 4. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two

2019 Scottish Medicines Consortium

48. Microneedles assisted incubation during aminolevulinic acid photodynamic therapy of actinic keratoses - a randomized controlled evaluator blind trial. Full Text available with Trip Pro

Microneedles assisted incubation during aminolevulinic acid photodynamic therapy of actinic keratoses - a randomized controlled evaluator blind trial. 27730625 2017 10 31 2017 10 31 1365-2133 176 2 2017 02 The British journal of dermatology Br. J. Dermatol. Microneedle-assisted incubation during aminolaevulinic acid photodynamic therapy of actinic keratoses: a randomized controlled evaluator-blind trial. 543-545 10.1111/bjd.15116 Lev-Tov H H Department of Dermatology and Cutaneous Surgery (...) Controlled Trial 2016 12 22 England Br J Dermatol 0004041 0007-0963 0 Photosensitizing Agents 88755TAZ87 Aminolevulinic Acid IM Aged Aged, 80 and over Aminolevulinic Acid administration & dosage Equipment Design Facial Dermatoses drug therapy Female Forehead Humans Keratosis, Actinic drug therapy Male Middle Aged Needles Pain etiology Pain Measurement Photochemotherapy instrumentation Photosensitizing Agents administration & dosage Prospective Studies Single-Blind Method 2016 10 13 6 0 2017 11 1 6 0 2016

2016 British Journal of Dermatology Controlled trial quality: predicted high

49. Long-term Outcome of Low-concentration Hexyl-5-aminolaevulinate Daylight Photodynamic Therapy for Treatment of Actinic Keratoses. Full Text available with Trip Pro

Long-term Outcome of Low-concentration Hexyl-5-aminolaevulinate Daylight Photodynamic Therapy for Treatment of Actinic Keratoses. 27304514 2017 01 26 2017 05 05 1651-2057 97 1 2017 01 04 Acta dermato-venereologica Acta Derm. Venereol. Long-term Outcome of Low-concentration Hexyl-5-aminolaevulinate Daylight Photodynamic Therapy for Treatment of Actinic Keratoses. 120-121 10.2340/00015555-2484 Neittaanmäki-Perttu Noora N Department of Dermatology and Allergology, Helsinki University Central (...) Hospital, FIN-00029 Helsinki, Finland. noora.neittaanmaki@fimnet.fi. Karppinen Toni Tapani TT Tani Taneli T Snellman Erna E Grönroos Mari M eng Journal Article Sweden Acta Derm Venereol 0370310 0001-5555 0 Photosensitizing Agents 88755TAZ87 Aminolevulinic Acid G7H20TKI67 5-aminolevulinic acid hexyl ester IM Aged Aminolevulinic Acid analogs & derivatives therapeutic use Head Humans Keratosis, Actinic drug therapy Male Pain Measurement Photochemotherapy Photosensitizing Agents therapeutic use Treatment

2016 Acta Dermato-Venereologica

50. Optical coherence tomography of actinic keratoses and basal cell carcinomas - differentiation by quantification of signal intensity and layer thickness. (Abstract)

Optical coherence tomography of actinic keratoses and basal cell carcinomas - differentiation by quantification of signal intensity and layer thickness. Previous studies have shown that actinic keratoses (AKs) and basal cell carcinomas (BCCs) can be diagnosed by optical coherence tomography (OCT) based on morphological characteristics. There is a lack of systematic studies that give standardized information on signal intensity and layer thickness of AKs and BCCs.The aim of this study

2016 Journal of the European Academy of Dermatology and Venereology

51. Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses. (Abstract)

Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses. Actinic keratosis (AK), a common cutaneous lesion with the potential to transform into squamous cell carcinoma, has traditionally been treated with ablative and/or surgical procedures. Recently, a topical formulation combining 0.5% 5-fluorouracil with 10% salicylic acid (5-FU-SA) was introduced in Europe under the trade name Actikerall™ for the treatment of grade I/II

2016 Skin therapy letter

52. Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp. Full Text available with Trip Pro

Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp. Aminolevulinic acid photodynamic therapy (ALA-PDT) can be effective and well tolerated when applied over a broad area and for short drug incubation times.To evaluate the effect of short-incubation time and application method on the safety and efficacy of ALA-PDT versus vehicle (VEH-PDT) in the treatment of actinic keratoses (AKs) of the face

2016 Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Controlled trial quality: uncertain

53. Artificial White Light vs Daylight Photodynamic Therapy for Actinic Keratoses: A Randomized Clinical Trial. Full Text available with Trip Pro

Artificial White Light vs Daylight Photodynamic Therapy for Actinic Keratoses: A Randomized Clinical Trial. Daylight photodynamic therapy using topical methyl 5-aminolevulinic acid (MAL) for actinic keratoses (AKs) is as effective as conventional photodynamic therapy but has the advantage of being almost pain free. Daylight photodynamic therapy, however, requires dry and warm weather conditions.To establish if topical MAL photodynamic therapy using a white light light-emitting diode (LED) lamp

2016 JAMA dermatology Controlled trial quality: uncertain

54. Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp - a randomized clinical trial. (Abstract)

Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp - a randomized clinical trial. The main side-effects of photodynamic therapy (PDT) for actinic keratoses (AKs) are post-treatment erythema and oedema, and pain during illumination. Severe erythema after PDT enhances the down time associated with the treatment.To evaluate in a randomized intraindividual study whether pulse-PDT and corticosteroid

2016 The British journal of dermatology Controlled trial quality: uncertain

55. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. (Abstract)

Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. Ingenol mebutate (IngMeb) is approved for treatment of actinic keratoses (AK) and may cause unpredictable local skin responses (LSR).We sought to investigate whether IngMeb-induced LSR, pain, and pruritus could be alleviated with a topical glucocorticoid and, further, to assess efficacy, cosmetic outcome, and patient

2016 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

56. Effect of a Pre-Treatment Educational Video in Improving Patient Satisfaction with 5-Fluorouracil Treatment for Actinic Keratoses: A Randomized Controlled Trial. Full Text available with Trip Pro

Effect of a Pre-Treatment Educational Video in Improving Patient Satisfaction with 5-Fluorouracil Treatment for Actinic Keratoses: A Randomized Controlled Trial. Patient treatment satisfaction and adherence may be affected by the initial understanding of outcomes in the treatment of actinic keratoses with 5-fluorouracil 5% cream (5-FU). Pre-treatment educational videos may optimize this understanding. The objective of this study was to determine whether prospective patient viewing (...) of an educational video delineating treatment effects and expectations improves patient satisfaction and treatment completion rates for the treatment of actinic keratoses with 5-FU.Forty-four participants were recruited to the UC Davis Dermatology outpatient clinic. Each participant was randomized to the video (group A) or control group (group B), and topical 5-FU cream treatment was conducted for 2 weeks in both groups.A follow-up questionnaire was performed to assess patient satisfaction and adherence

2016 Dermatology and therapy Controlled trial quality: uncertain

57. Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study. Full Text available with Trip Pro

Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study. Introduction. Actinic keratoses (AKs), a premalignant skin lesion, are a common lesion in fair skin. Although destructive treatment remains the gold standard for AKs, medical therapies may be preferable due to the comfort and reliability .This study aims to compare the effects of topical 1% colchicine gel and 3% diclofenac sodium gel in AKs. Materials and Methods

2016 Advances in medicine Controlled trial quality: uncertain

58. Pharmacoeconomy of drugs used in the treatment of actinic keratoses Full Text available with Trip Pro

Pharmacoeconomy of drugs used in the treatment of actinic keratoses Actinic keratosis (AK) represents an emerging issue in the area of skin diseases which undergo high risk for developing squamous cell carcinoma (SCC). Recently, evidence has been accumulated that 3% diclofenac sodium and ingenol mubetate may efficiently counteract the development of progressive AK even if the pharmacoeconomic impact of such a treatment remains poorly defined. With the objective of assessing the efficacy of 3

2016 International journal of immunopathology and pharmacology

59. Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study Full Text available with Trip Pro

Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study Actinic keratoses (AKs), especially on areas of the face, have a negative impact on a patient's quality of life (QoL). These lesions manifest on sun-damaged skin and have the potential to progress to squamous cell carcinoma. Field-directed therapy alone and in combination with lesion-directed treatment is effective in clearing both visible and nonvisible AK

2016 Clinical, cosmetic and investigational dermatology

60. Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States

Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States (DaylightPDT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02867722

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>